A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
Titel:
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression
Auteur:
Li, D. Pant, S. Ryan, D.P. Laheru, D. Bahary, N. Dragovich, T. Hosein, P.J. Rolfe, L. Saif, M.W. LaValle, J. Yu, K.H. Lowery, M.A. Allen, A. O'Reilly, E.M.